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O B J E C T I V E S This study sought to examine and compare the incidence and progression of
coronary artery calcium (CAC) among persons with metabolic syndrome (MetS) and diabetes mellitus
(DM) versus those with neither condition.
B A C KG ROUND MetS and DM are associated with subclinical atherosclerosis as evidenced by CAC.
METHOD S The MESA (Multiethnic Study of Atherosclerosis) included 6,814 African American, Asian,
Caucasian, and Hispanic adults 45 to 84 years of age, who were free of cardiovascular disease at baseline.
Of these, 5,662 subjects (51% women, mean age 61.0  10.3 years) received baseline and follow-up
(mean 2.4 years) cardiac computed tomography scans. We compared the incidence of CAC in 2,927
subjects without CAC at baseline and progression of CAC in 2,735 subjects with CAC at baseline in those
with MetS without DM (25.2%), DM without MetS (3.5%), or both DM and MetS (9.0%) to incidence and
progression in subjects with neither MetS nor DM (58%). Progression of CAC was also examined in
relation to coronary heart disease events over an additional 4.9 years.
R E S U L T S Relative to those with neither MetS nor DM, adjusted relative risks (95% conﬁdence
intervals [CI]) for incident CAC were 1.7 (95% CI: 1.4 to 2.0), 1.9 (95% CI: 1.4 to 2.4), and 1.8 (95% CI: 1.4
to 2.2) (all p  0.01), and absolute differences in mean progression (volume score) were 7.8 (95% CI: 4.0
to 11.6; p  0.01), 11.6 (95% CI: 2.7 to 20.5; p  0.05), and 22.6 (95% CI: 17.2 to 27.9; p  0.01) for those
with MetS without DM, DM without MetS, and both DM and MetS, respectively. Similar ﬁndings were seen
in analysis using Agatston calcium score. In addition, progression predicted coronary heart disease events in
those with MetS without DM (adjusted hazard ratio: 4.1, 95% CI: 2.0 to 8.5, p 0.01) and DM (adjusted hazard
ratio: 4.9 [95% CI: 1.3 to 18.4], p 0.05) among those in the highest tertile of CAC increase versus no increase.
CONC L U S I O N S Individuals with MetS and DM have a greater incidence and absolute progression
of CAC compared with individuals without these conditions, with progression also predicting coronary
heart disease events in those with MetS and DM. (J Am Coll Cardiol Img 2012;5:358–66) © 2012 by the
American College of Cardiology Foundation
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359etabolic syndrome (MetS) and diabetes
(DM) predict coronary heart disease
(CHD) events and mortality (1–3).
Subclinical atherosclerosis as evidenced
y coronary artery calcium (CAC) (4–9) and ca-
otid intima-media thickness (10,11) is increased in
etS and DM, but no study has compared the
ncidence and progression of CAC across these
onditions. Progression of CAC may be clinically
mportant because persons experiencing CHD
vents have greater progression of CAC (12) and,
ecently, progression of CAC has been shown to
redict all-cause mortality (13). The population-
See page 367
based MESA (Multiethnic Study of Atherosclero-
sis) has demonstrated that most standard CHD risk
factors are associated with the incidence and pro-
gression of CAC (14).
In this report, we compared, in MESA, the
incidence and progression of CAC among persons
with MetS (but no DM) and DM (with and without
MetS) relative to those with neither condition. Our
hypothesis was that MetS subjects would be associated
with future development and progression of CAC
greater than those subjects without MetS would, but
less than those with DM would.
M E T H O D S
Study population and deﬁnitions. The design of
ESA, a prospective epidemiologic study of the
revalence, risk factors, and progression of subclin-
cal cardiovascular disease has been previously pub-
ished (15). Briefly, 6,814 participants 45 to 84
ears of age, who were free of clinical cardiovascular
isease and identified as White, African American,
ispanic, or Chinese were recruited from 6 U.S.
ommunities (Forsyth County, North Carolina;
Johns Hopkins University, Baltimore, Maryland; ¶The Heart Center, St.
Francis Hospital, Roslyn, New York; #Division of Epidemiology and
Community Health, University of Minnesota, Minneapolis, Minnesota;
**Department of Preventive Medicine, Northwestern University, Chicago,
Illinois; ††Carnitas Carney Hospital, Boston, Massachusetts; ‡‡Depart-
ment of Pathology, University of Vermont, Burlington, Vermont; and the
§§University of Oslo, Oslo, Norway. This research was supported by
contracts N01-HC-95159 through N01-HC-95165 and N01-HC-95169
from the National Heart, Lung, and Blood Institute. Dr. Wong reports
research funding from Bristol-Myers Squibb through the University of
California, Irvine. Dr. Nelson has been a statistical consultant for Glaxo-
SmithKline. All other authors have reported that they have no relationships
relevant to the contents of this paper to disclose.s
Manuscript received July 24, 2011; revised manuscript received December
8, 2011, accepted December 22, 2011.orthern Manhattan and the Bronx, New York;
altimore City and Baltimore County, Maryland;
t. Paul, Minnesota; Chicago, Illinois; and Los
ngeles County, California) from 2000 to 2002.
ecruitment included lists of residents, dwellings,
elephone exchanges, lists of Medicare beneficiaries,
nd referrals by participants. Similar numbers of
en and women were recruited according to pre-
pecified age and race/ethnicity quotas. All participants
ave informed consent, and the study protocol was
pproved by the Institutional Review Board at each site.
This report includes 5,662 subjects with both
aseline (Exam 1) and follow-up (at Exams 2 or 3)
omputed tomography (CT) scans, available data to
efine DM or MetS, and with no incident CHD
vent occurring between baseline and follow-up
T. This resulted in excluding 1,056 subjects who
id not have follow-up scans (or were out of
rotocol), 26 with incomplete data to define DM or
etS, and 70 who had an intervening CHD event.
iabetes was defined as having a fasting
lucose7.0 mmol/l (126 mg/dl) or being
n insulin or oral hypoglycemic medica-
ions. Among nondiabetics, MetS was de-
ned to be present if 3 of the following
ere present: 1) abdominal obesity based
n waist circumference 88 cm (35
nches) for women and102 cm (40 inches)
or men; 2) high-density lipoprotein choles-
erol 1.0 mmol/l (40 mg/dl) for men or
1.3 mmol/l (50 mg/dl) for women;
) fasting triglycerides 1.7 mmol/l (150
g/dl); 4) blood pressure of130 mm Hg
ystolic or 85 mm Hg diastolic, or on treatment; or
) impaired fasting glucose defined as a fasting glucose of
.55 to 6.99 mmol/l (100 to 125 mg/dl), based on the
merican Heart Association/National Heart, Lung, and
lood Institute definition (16).
Measurement of CAC. CAC was measured by
lectron-beam (3 sites) or multidetector (3 sites)
T. Participants were scanned twice consecutively
nd scans were read by a trained physician-reader at
centralized reading center (Los Angeles Biomed-
cal Research Institute, Torrance, California). The
ethodology for acquisition and interpretation of
he scans has been published (17). Calcium volume
cores (17) and Agatston scores (18) were based on
veraging results from each scan and adjusted using
standard calcium phantom (scanned with the
articipant) to calibrate X-ray attenuation between
easurements conducted on different machines
19). Detectable calcium was defined as a CAC
A B B
A N D
CAC
CHD
CI c
CT
DM
MetS
MI
RRcore0. A second scan was performed on onR E V I A T I O N S
A C R O N YM S
coronary artery calcium
coronary heart disease
onfidence interval
computed tomography
diabetes mellitus
metabolic syndrome
myocardial infarctione-half
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360of the cohort (randomly selected) at a second exam
(September 2002 to January 2004) and on the other
one-half at a third exam (March 2004 to July 2005),
averaging 1.6 and 3.2 years after the first scan,
respectively (average 2.4 years between). The dis-
tribution of CAC in MESA at baseline by age, sex,
and race has been published previously (20).
Examination data and covariates. Information on de-
ographics, smoking, medical conditions, and fam-
ly history was obtained by questionnaire. Height,
eight, total and high-density lipoprotein choles-
erol, triglycerides, and fasting glucose levels were
etermined. Resting blood pressure was measured 3
imes, with the average of the last 2 measurements
sed in analysis. Use of cholesterol, blood pressure,
nd diabetes medications was determined by ques-
ionnaire and from medication containers (15).
Follow-up for CHD events. The cohort was followed
or incident CHD events for a mean of 4.9  1.3
ears following the second scan. At intervals of 9 to
2 months, a telephone interviewer inquired about
nterim hospital admissions, cardiovascular diagno-
es, and deaths. An adjudication committee re-
eived copies of all death certificates and medical
ecords for hospitalizations and outpatient cardio-
ascular diagnoses and conducted next-of-kin inter-
iews. Two physicians independently classified and
ssigned incidence dates. For disagreements, a full
ortality and morbidity review committee made
he final classification. We followed participants for
ccurrence of all CHD endpoints, which included
yocardial infarction, angina, resuscitated cardiac
rrest, or CHD death. CHD death was based on
eview of hospital records and interviews with
amilies. The reviewers were blinded to CT scan
nd cardiac magnetic resonance results and used
re-specified criteria.
Statistical analysis. Subjects were classified as hav-
ng: 1) neither MetS nor DM; 2) MetS without
M; 3) DM without MetS; and 4) DM with
etS. The first 2 groups were also classified by
umber of MetS risk factors (0, 1, 2, 3, and 4 to 5).
o assess bivariate associations between these
roups, risk factors, and CAC score/volume mea-
ures, the chi-square test (for categorical covariates)
r an F test from analysis of variance (for continu-
ous covariates) was used. Incident CAC was de-
fined among those without baseline CAC (n 
2,927) as those who developed detectable CAC at
the follow-up scan. Absolute progression of CAC
was defined among those with CAC at baseline
(n  2,735) as the difference between the CAC
volume score on follow-up (CACFU) and that ataseline (CACBL) (14). We used relative risk (RR)
regression (21) to obtain asymptotically unbiased
estimates of the RR of incident CAC among those
free of CAC at baseline. This involved modeling
the probability of incident CAC score as an expo-
nential function of risk factors (including each
MetS/DM classification relative to the reference
group) and performing nonlinear least-squares es-
timation. To account for misspecification of the
variance, we computed model-robust (Huber-
White) standard errors. To estimate the absolute
progression of CAC among those with detectable
CAC at baseline, we used robust linear regression,
down-weighting the influence of participants with
very large progression to increase model robustness.
We also present our findings as relative progression,
defined as the median annualized percentage of
change in CAC from baseline to follow-up scan.
Our analyses also adjusted for time between scans,
age, sex, ethnicity, baseline total cholesterol, lipid-
lowering medication use, smoking status, and fam-
ily history of myocardial infarction. Adjusting for
the time between scans in a progression model of
the absolute change in CAC implicitly standardizes
CAC change with respect to time and is equivalent
to directly modeling the annualized absolute CAC
change. Absolute progression analyses (but not
relative progression) were additionally adjusted for
the scanner pair used at baseline and follow-up to
account for scanner changes over time. As a sensi-
tivity analysis, we also performed progression anal-
yses additionally adjusted for baseline calcium vol-
ume score. We also investigated the independent
contribution of each MetS component to predicting
the incidence or progression of CAC, and we
evaluated incidence and progression models that
included each of the 5 separate MetS components
in the model together. To examine if the composite
of MetS/DM still predicted incidence and progres-
sion of CAC after accounting for the individual
MetS components, we added this in a final model.
Finally, Cox proportional hazards regression was
used to examine the relation of progression of CAC
to the incidence of total CHD events within each
disease group separately. All statistical analyses were
performed using SAS (version 9.1, SAS Institute,
Cary, North Carolina) (22).
R E S U L T S
Overall, 5,662 subjects were included (51% women,
mean age 61.0  10.3 years): 3,528 (62.3%) had
neither MetS nor DM; 1,426 (25.2%) had MetS
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361without DM; 198 (3.5%) had DM without MetS;
and 510 (9.0%) had both MetS and DM. Subjects
excluded (n  70) because of intervening CHD
vents between baseline and follow-up scans were
ore likely to have both MetS and DM (23%) and
ess likely to have neither condition (40%); also,
1% had MetS (without DM) and 6% had DM
ithout MetS. Scanners used for the initial and
ollow-up scan were electron-beam CT (n  2,852,
50.4%), multidetector (n  2,630, 46.4%), and the
remainder were electron-beam multidetector (n 
180, 3.2%). Table 1 shows the distribution of
demographic and clinical risk factors and calcium
scores by the 4-category MetS/DM classification.
Systolic and diastolic blood pressure, triglycerides,
and waist circumference were highest and high-
density lipoprotein cholesterol was lowest in those
with MetS, and fasting glucose levels were high-
est in those with DM (all p  0.01). The
prevalence of CAC ranged from 44% to 62% by
MetS/DM classification (p  0.01). Among those
Table 1. Baseline Risk Factor Distributions and Baseline and Fo
N
(n
Age, yrs*
Women*
Ethnicity*
Caucasian
Chinese American
African American
Hispanic
Current smoker
Family history of MI*
Fasting glucose, mg/dl*
Triglycerides, mg/dl*
Systolic BP, mm Hg*
Diastolic BP, mm Hg*
Waist circumference, cm*
HDL cholesterol, mg/dl*
Total cholesterol, mg/dl*
Prevalence of calcium*
Baseline volume score (all subjects N  5,662)*
Follow-up volume score (all subjects N  5,662)*
Baseline volume score (baseline CAC  0, n  2,735)*
Follow-up volume score (baseline CAC  0, n  2,735)*
Baseline Agatston score (all subjects N  5,662)*
Follow-up Agatston score (all subjects N  5,662)*
Baseline Agatston score (baseline CAC  0, n  2,735)*
Follow-up Agatston score (baseline CAC  0, n  2,735)*
Values are n (%), %, or mean  SD. *p  0.001 across groups. †Tests for associa
are 1,547, 761, 113, and 314 for those with neither MetS nor DM, MetS withou
BP  blood pressure; CAC  coronary artery calcium; DM  diabetes mellitus; HDwith CAC, baseline volume score was highest in
those with DM.
The unadjusted incidence of CAC increased
progressively according to MetS/DM status
(Fig. 1). Among men with DM and women with
DM plus MetS, incidence of CAC was highest.
Incidence was unexpectedly low, however, in
women with DM but without MetS (although
uncertain because of a low sample size).
Table 2 shows the adjusted RRs for incident
CAC for the 4- and 7-category MetS/DM classi-
fications. Compared with those with neither MetS
nor DM, those with MetS (without DM) and those
with DM (regardless of the presence of MetS) had
a greater incidence of CAC. In gender-stratified
analyses, results were generally similar to the overall
group, except for those with DM (without MetS)
where findings were not significant for women. In
analyses stratified by ethnicity (results not shown),
the RR for incident CAC was significantly greater
for those with both DM and MetS among Chinese
-Up Coronary Calcium Volume and Scores by MetS and DM Grou
Exposure
etS, No DM
,528, 62.3%)
MetS, No DM
(n  1,426, 25.2%)
No MetS, DM
(n  198, 3.5%)
.0 (10.3) 62.6 (9.9) 64.3 (9.6)
51.3 58.8 31.8
43.2 40.1 19.7
12.9 9.6 17.2
25.8 24.9 38.4
18.2 25.4 24.8
12.1 13.0 13.6
38.6 43.4 30.3
.9 (8.6)† 95.2 (11.9)† 133.2 (53.0)†
.1 (57.5)† 181.7 (88.5)† 99.7 (49.2)†
.7 (20.2) 133.1 (20.2) 126.4 (18.8)
.1 (10.0) 73.9 (10.4) 71.9 (10.2)
.6 (13.3) 105.5 (12.4) 95.7 (11.8)
.2 (14.9) 42.9 (10.0) 53.5 (13.6)
.3 (33.3) 196.6 (37.5) 184.5 (33.1)
43.9 53.4 57.1
.5 261.4 107.3 281.6 193.2 477.1
.0 318.7 150.3 358.3 282.9 609.2
.6 367.5 201.0 360.4 338.6 592.3
.9 442.5 279.8 452.4 493.7 740.4
.7 334.6 138.5 365.4 244.9 608.3
.9 414.2 196.1 468.2 362.9 784.7
.3 471.3 259.5 467.9 429.1 755.7
.5 576.1 365.2 591.2 633.5 954.4
done on mean of log-transformed data. Among analyses in those with CAC 0, d
, DM without MetS, and DM plus MetS, respectively.llow ping
o M
 3
Both MetS and DM
(n  510, 9.0%)
61 63.9 (9.4)
53.1
20.6
9.6
37.1
32.8
12.6
40.6
86 152.0 (52.4)†
104 184.1 (152.8)†
121 133.7 (21.6)
71 71.6 (10.2)
93 108.0 (13.6)
55 43.8 (11.7)
194 189.9 (40.7)
61.6
84 171.4 364.2
112 257.6 512.4
192 278.4 431.0
253 416.6 600.8
106 221.0 469.6
143 337.7 674.9
243 359.0 555.8
326 546.3 791.9
tion isease group sample sizes
t DML  high-density lipoprotein; MetS  metabolic syndrome; MI  myocardial infarction.
syndrome.
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362(RR  3.7, p  0.05), Hispanics (RR  2.2, p 
0.01), and African Americans (RR 1.8, p 0.05)
and was also greater for those with MetS without
DM in all ethnic groups (RR 1.7 to 2.1, p 0.05
to p  0.01). Only in African Americans was
incident CAC significantly greater (RR  2.1, p 
0.05) for those with DM (without MetS) versus
those without MetS or DM. When examining
CAC incidence by number of MetS risk factors,
compared with those with no MetS risk factors,
those with as few as 2 MetS risk factors had an
increased incidence of CAC (RR  1.5, p  0.05),
with increases to RRs of 2.0 or greater in those with
3 or 4 to 5 MetS risk factors, DM without MetS, or
Women
4.3
8.5
3.4
9.6
6.2
11.5
13.9
12.9
Men
No MetS/No DM MetS/No DM No MetS/DM Both MetS/DM
cidence of CAC (per 100 Person Years) According to MetS and
by Sex, Among Persons Without Baseline CAC
nary artery calcium; DM  diabetes mellitus; MetS  metabolic
Table 2. RR Regression for Incidence of CAC Among Persons W
by Number of MetS Risk Factors: Incidence and Risk Ratio Estim
Exposure n
Overall Adjusted RR
(95% CI)*
Both DM and MetS 196 2.0 (1.5 – 2.8)†
DM and No MetS 85 1.6 (1.0 – 2.6)‡
MetS and No DM 661 1.8 (1.5 – 2.2)†
Neither MetS nor DM 1,976 1.0
Both DM and MetS 196 2.6 (1.7 – 3.9)†
DM and No MetS 85 2.1 (1.2 – 3.5)†
No. of MetS risk factors
4–5 216 2.2 (1.5 – 3.3)†
3 445 2.3 (1.6 – 3.3)†
2 688 1.5 (1.1 – 2.1)‡
1 741 1.2 (0.9 – 1.7)
0 547 1.0
*Estimates adjusted for age, sex (except in sex-stratiﬁed analyses), ethnicity, tim
family history of MI, and scanner pair. †p  0.01 compared reference group of n
and are not reﬂected in these analyses. ‡p  0.05.
CI  conﬁdence interval; RR  relative risk; other abbreviations as in Table 1.both DM and MetS (p  0.01 overall), with
stronger associations seen in women.
Among those with baseline CAC, progression of
CAC (median annualized percent change in CAC)
also increased directly according to MetS/DM sta-
tus (Fig. 2). Robust linear regression (Table 3)
showed those with both MetS and DM as well as
those with DM but no MetS to have the greatest
progression of CAC, and those with MetS but not
DM to have an intermediate level of progression.
Women with DM and no MetS and men with both
DM and MetS had the greatest degree of progres-
sion of CAC. Among each individual ethnic group,
progression of CAC was greatest in those with both
MetS and DM (mean adjusted volume score dif-
ferences of 15.3 to 27.1, p  0.01, compared with
those with neither MetS nor DM), being highest in
Caucasians (23.4) and African Americans (27.1).
Of other MetS/DM groups, only DM without
MetS in African Americans (31.7, p  0.01) and
Chinese (17.5, p 0.05) and MetS without DM in
Caucasians (11.0, p  0.01) had progression sig-
nificantly greater than those with neither MetS nor
DM did. In analyses by number of MetS risk
factors (Table 4), compared with those with 0 MetS
risk factors, progression was greater only for those
with 3 MetS risk factors, DM, or both DM and
MetS. The greatest increases were seen for those
with DM with MetS. Although in sex-stratified
analyses, this was the case for men, but not for
women where DM without MetS had the great-
est progression. Results presented according to
ut CAC at Baseline (n  2,918) by MetS and DM Grouping and
s by Sex
n
Women Adjusted RR
(95% CI)* n
Men Adjusted RR
(95% CI)*
130 2.0 (1.3 – 3)† 66 2.0 (1.2 – 3.2)†
35 0.8 (0.2 – 2.5) 50 2.0 (1.2 – 3.4)†
456 1.9 (1.4 – 2.4)† 205 1.7 (1.2 – 2.4)†
209 1.0 767 1.0
130 3.1 (1.7 – 5.7)† 66 2.2 (1.2 – 3.9)†
35 1.2 (0.3 – 4) 50 2.4 (1.3 – 4.3)†
155 2.8 (1.6 – 5.1)† 61 1.6 (0.8, – 3)
301 2.8 (1.6 – 4.8)† 144 2 (1.3 – 3.3)†
454 1.8 (1.1 – 3.1)‡ 234 1.2 (0.7 – 1.9)
451 1.4 (0.8 – 2.4) 290 1.1 (0.7 – 1.8)
304 1.0 243 1.0
tween scans, smoking status, total cholesterol, lipid-lowering medications use,
r MetS nor DM, or No MetS risk factors; 9 observations were missing covariates0
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363Agatston score showed similar findings with the
expected greater magnitude of differences due to
absolute Agatston scores being higher than vol-
ume scores.
When additionally adjusting for baseline vol-
ume score, our findings regarding progression of
CAC were not substantially affected and re-
mained statistically significant. Mean differences
(compared with those subjects with neither MetS
nor DM) in volume score change were 6.2 (95%
confidence interval [CI]: 3.0 to 9.4) for those
with MetS without DM, 13.4 (95% CI: 6.5 to
20.4) for those with DM without MetS, and 14.6
(95% CI: 10.1 to 19.1) for those with DM and
MetS (all p  0.01).
We also evaluated the relation of individual
MetS components to the incidence and progression
of CAC. With all components in the model simul-
taneously, only increased waist circumference (ad-
justed RR  1.4, p  0.001) and increased glucose
adjusted RR  1.25, p  0.01) predicted CAC
ncidence. Progression of CAC was driven most
trongly by elevated glucose (volume score change
f 10.7, p  0.001) and blood pressure (volume
core change of 5.8, p  0.05).
When examining the relation of CAC progres-
ion to total CHD events in each disease group,
otal CHD events per 1,000 person years in-
reased progressively according to extent of
hange in volume score in those with neither
etS nor DM, those with MetS and no DM, and
hose with both MetS and DM (Fig. 3). Corre-
ponding hazard ratios, adjusted for age, sex,
thnicity, and risk factors, compared with those
ubjects with no or negative change, were in-
Table 3. Multivariable Analysis of Absolute Progression of Coro
A
Exposure n
Robu
Me
Agatston score Both 314 29
DM and No MetS 113 25
MetS and Nondiabetic 758 8
Neither MetS nor DM 1,544 0
Volume score Both 314 22
DM and No MetS 113 16
MetS and Nondiabetic 758 7
Neither MetS nor DM 1,544 0
Adjusted for age, sex (except in sex-stratiﬁed analyses), ethnicity, time between
Relative risk regression adjusted for age, sex (except in sex-stratiﬁed analyses), e
MI, and scanner pair; reference group comprises those with neither MetS nor D
in these analyses. †p  0.05.
Abbreviations as in Tables 1 and 2.reased in those subjects in the second and third
ertiles of positive CAC change: 4.5 (95% CI: 2.2
o 9.4), p  0.01 and 7.6 (95% CI: 3.7 to 15.5),
 0.01, respectively in those subjects with
either MetS nor DM, 2.3 (95% CI: 1.0 to 4.9),
 0.05 and 4.1 (95% CI: 2.0 to 8.5), p  0.01,
espectively, in those subjects with MetS and no
M and 4.0 (95% CI: 1.1 to 14.9), p  0.05 and
.9 (95% CI: 1.3 to 18.4), p  0.05, respectively,
n those subjects with both MetS and DM. After
dditional adjustment for baseline CAC, these
stimates were similar: 4.5 (95% CI: 2.2 to 9.4),
 0.01 and 7.0 (3.4 to 14.7), p  0.01,
espectively, in those subjects with neither MetS
or DM, 2.3 (95% CI: 1.1 to 5.0), p  0.05 and
.5 (95% CI: 1.6 to 7.3), p  0.01, respectively,
n those subjects with MetS and no DM and 3.9
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y Calcium by MetS/DM Status Among Persons With CAC at Baseli
Women
ifference in
rogression
5% CI) n
Robust Difference in
Mean Progression
(95% CI) n
1.8 – 36.7)* 141 20.8 (11.7 – 29.8)* 173
3.5 – 36.5)* 28 38.6 (20.4 – 56.8)* 85
.0 – 13.5)* 379 3.6 ( – 2.6 – 9.8) 379
.0 – 0.0) 596 0.0 (0.0 – 0.0) 948
6.9 – 27.9)* 141 16.3 (9.4 – 23.2)* 173
.1 – 25.2)* 28 26.4 (12.5 – 40.4)* 85
.5 – 11.3)* 379 5.2 (0.5 – 10.0)† 379
.0 – 0.0) 596 0.0 (0.0 – 0.0) 948
ns, smoking status, total cholesterol, lipid-lowering medications use, family histor
city, time between scans, smoking status, total cholesterol, lipid-lowering medicat
 0.01 compared with neither MetS nor DM; 6 observations were missing covari32.3
h MetS/DM
ge in
ng Personsnar ne (n  2,729)
ll Men
st D
an P
(9
Robust Difference in
Mean Progression
(95% CI)
.3 (2 35.4 (24.0 – 46.8)*
.0 (1 21.9 (6.4 – 37.4)*
.2 (3 15.4 (7.2 – 23.7)*
.0 (0 0.0 (0.0 – 0.0)
.4 (1 26.6 (18.3 – 34.9)*
.7 (8 14.2 (3.0 – 25.5)†
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sca y of MI, and scanner pair.
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M. *p ates and are not reﬂected
Figure 1.
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364(95% CI: 1.0 to 14.8), p  0.05 and 4.0 (95% CI:
0.95 to 16.0), p  NS, respectively, in those with
both MetS and DM.
D I S C U S S I O N
In the MESA, persons with MetS or DM have a
greater incidence and progression of CAC than
those subjects without MetS, and those with
Neither MetS/DM MetS w/o DM DM + MetS
1.2
3.7
8.8
17.7
4.2
7.7
10.7
26.4
3.3
9.3
17.5
30.7
No CAC Increase 1st Tertile 2nd Tertile 3rd Tertile
HD Event Rates (per 1,000 Person Years) According to Tertile
gression by Presence of MetS and DM
t shown for persons with DM without MetS because of an insufﬁ-
er of coronary heart disease (CHD) events. Abbreviations as in
Analysis of Absolute Progression of Coronary Calcium by Numb
All
Exposure n
Robust Difference in
Mean Progression
(95% CI) n
Both 314 32.4 (22.5–42.2)* 141
DM and no MetS 113 28.0 (14.8–41.1)* 28
4–5 MetS risks 294 12.9 (3.1–22.8)† 159
3 MetS risks 464 10.5 (1.5–19.4)† 220
2 MetS risks 650 5.9 (2.5–14.4) 292
1 MetS risk 613 1.6 (6.9–10.0) 217
0 MetS risks 281 0.0 (0.0–0.0) 87
Both 314 23.7 (16.3–31.0)* 141
DM and no MetS 113 17.9 (8.1–27.7)* 28
4–5 MetS risks 294 10.9 (3.5–18.2)* 159
3 MetS risks 464 7.5 (0.8–14.1)† 220
2 MetS risks 650 3.9 (2.4–10.1) 292
1 MetS risk 613 1.0 (7.3–5.3) 217
0 MetS risks 281 0.0 (0.0–0.0) 87
usted for age, sex (except in sex-stratiﬁed analyses), ethnicity, time between scan
group comprises those with 0 MetS risk factors. *p  0.01 compared to 0 MetS
s 1 and 2.MetS (without DM) have an intermediate inci-
dence and progression. Also, insulin resistance
(23) and DM (24,25) have been shown in smaller
or selected cohorts to relate to progression of
CAC, and in those with DM, a glycated hemo-
globin 7% predicted progression of CAC (26).
Progression of CAC has also been shown to
predict total mortality over baseline risk factors
and CAC (13). In our study, we also found
increased progression of CAC in persons with
MetS and DM to predict future CHD events.
The baseline calcium score, a strong predictor of
CAC progression, is important to understanding
the relationship of MetS and DM to progression of
CAC (23,27). Because MetS is associated with an
intermediate level and DM the highest level of
CAC, we might expect a similar pattern for pro-
gression. Whereas baseline CAC could be consid-
ered a confounder, it can also be considered part of
the causal pathway between risk factors such as
MetS and DM and the progression of CAC. Such
persons likely had more rapid progression of
CAC to begin with and continued to show
greater future progression; hence, including base-
line CAC in the model could condition out the
effects that variables of interest (in this case,
MetS and DM) may have up to baseline (14). In
our study, however, secondary analyses addition-
f MetS Risk Factors/DM Status Among Persons With CAC at
Women Men
Robust Difference in
Mean Progression
(95% CI) n
Robust Difference in
Mean Progression
(95% CI)
20.8 (7.9–33.6)* 173 38.8 (24.3–53.3)*
38.5 (18.5–58.6)* 85 25.3 (7.4–43.2)*
5.7 (6.7–18.0) 135 23.0 (7.7–38.2)*
4.3 (7.5–16.0) 244 16.8 (3.7–29.9)†
4.5 (6.8–15.7) 358 4.5 (7.7–16.6)
2.1 (13.6–9.5) 396 4.2 (7.8–16.2)
0.0 (0.0–0.0) 194 0.0 (0.0–0.0)
18.5 (8.5–28.5)* 173 26.9 (16.3–37.4)*
28.9 (13.3–44.5)* 85 14.6 (1.5–27.6)†
10.1 (0.5–19.7)† 135 14.6 (3.5–25.7)*
6.4 (2.7–15.5) 244 9.5 (0.0–19.1)
5.8 (3.0–14.6) 358 1.2 (7.7–10.0)
0.4 (9.4–8.6) 396 0.3 (9.0–8.4)
0.0 (0.0–0.0) 194 0.0 (0.0–0.0)
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365only a slight attenuation of our findings, which
remained largely significant.
In addition, the choice of the scale for continuous
progression (e.g., absolute vs. relative change) and
the failure to account for outlying progressors may
markedly influence the results obtained (14). Sim-
ilar to Kronmal et al. (14), we use absolute progres-
sion as our primary outcome and account for
outlying progressors using robust regression mod-
eling techniques, which limits the influence of
outlying observations (e.g., fast progressors).
Strengths of MESA include its large sample size,
ethnic diversity, and community-based recruitment.
The prospective design allows for assessment of
baseline factors including MetS and DM in relation
to development and progression of CAC, as well as
the evaluation of progression of CAC in relation to
subsequent CHD events. In addition, MESA had
standardized protocols for scanning and interpreta-
tion of scans. Importantly, our estimate of progres-
sion of CAC was based only on the change between
2 scans done an average of about 2 years apart, from
which progression was then annualized. However,
this assumes a linear relation of progression with
time, which may or may not be the case, hence
results could be different had more measures been
available and/or if the time between scans was
greater. Also, exclusion of a small number of indi-
viduals (n  70) who had intervening CHD events
may have influenced the results. Such persons weresyndrome to calcified atherosclerotic
1
heart disease andCAC, as well as CHD events, so our findings
relating progression to events could have been
underestimated (thus conservative). However, our
intention was to look at the natural progression of
CAC not interrupted by CHD events, thus we kept
our group homogenous by excluding such individ-
uals. As there is controversy of which definition
may be most appropriate, or even whether MetS
should be considered a syndrome (28–30), our
findings may have differed had other definitions for
MetS been used.
Persons with both MetS and DM have the
greatest incidence and degree of progression of
CAC. Those with MetS without DM have an
incidence and degree of progression of CAC inter-
mediate between those with DM and without these
conditions. Moreover, in those with MetS or DM,
progression predicts future CHD event risk.
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